NicOx S.A. (Euronext Paris: COX) announced an additional analysis of the blood pressure data from the 301 phase 3 study, showing a statistically significant difference between naproxcinod and naproxen in terms of the mean change from baseline in systolic and diastolic blood pressure at week 13 (p
Recent Posts
- Breakthrough Attracts Funding For Hypertension Research
- FDA Licenses First Biologic Product To Prevent Hepatitis B Reinfection In Liver Transplant Patients
- International Law Permits Abusive Fathers Custody Of Children
- Margaret Kripke Legend Award Won My Cancer Genetics Pioneer
- The Scent Of Lung Cancer Recognized By Sniffer Dogs
- New Pixantrone Data Presented At Meetings At American Society Of Hematology Conference
- The History Of Glivec
- Decoding Leukemia Patient Genome Leads Scientists To Mutations In Other Patients
- Hospitals Striving To Reduce Heart Attack Treatment Times
- In Bid To End Elephantiasis, DNA Barcoding Of Mosquito Species Deployed
- 'Victrelis'™ Added To Peginterferon Alfa-2a And Ribavirin Gives Higher Cure Rates In Treatment-Failure Patients With Chronic HCV Genotype 1